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合成 Z-十八碳-9-烯-丙磺酰胺( N15 )；采用 CCK-8 法检测 N15 对人脐静脉内皮
细胞活性的影响；采用转录激活检测 N15 对 PPARs 的激活作用；应用实时定量
逆转录聚合酶链式反应(Real-time PCR)和酶联免疫吸附检测( ELISA ) 分别在转
录水平（RNA 水平）和翻译水平（蛋白水平）测定 N15 对粘附分子 ICAM-1、
VCAM-1、E-选择素的表达的影响；采用细胞粘附实验检测 N15 对人急性单核白
血病细胞（THP-1）的粘附的影响。 















达抑制作用显著，尤其对 VCAM-1 的抑制作用明显，但对 E-选择素表达没有影
响；加入 PPAR-α拮抗剂 MK886 后，N15 对 VCAM-1 抑制作用消失，对 ICAM-1
抑制作用没有变化，表明 N15 是通过激活 PPAR-α发挥着抑制粘附分子 VCAM-1
表达的作用；此外，N15 对 THP-1 的粘附作用有明显的抑制效果，进一步表明
了 N15 对粘附分子表达的抑制。 



















Background: Atherosclerosis (AS) is one of the most severe factors that cause of 
cardiovascular diseases and seriously threatens the public health. In industrialized 
countries, Its Morbidity and mortality both accounted first for various diseases. With 
the standard of living and an aging population, the incidence of atherosclerosis is 
increasing in the developing countries including China. Therefore, the drugs on anti- 
atherosclerosis have become a focus of pharmaceutical research. Various studies 
showed that peroxisome proliferator-activated receptors (PPARs) had an important 
relationship with cardiovascular disease, diabetes, obesity, cancer. One of PPARs 
isoforms-- PPAR-α interferes with early steps in atherosclerosis by reducing leukocyte 
adhesion to activated endothelial cells of arterial vessel wall and inhibiting subsequent 
transendothelial leukocyte migration. The exsited PPAR-α synthesis ligand 
Fenofibrate has become first-line drugs for clinical treatment of cardiocascular disease. 
The endogenous PPAR-α ligand oleoyethanolamide (OEA) showed a significant role 
in the anti-atherosclerosis. 
Purpose ： To investigate the effect and mechanism of OEA analogue 
Propane-2-sulfonic acid octadec-9-enyl-amide(N15)，we detect the expression of 
adhension moleculars in TNF-α induced HUVEC。 
Methods：HUVECs were pretreated with different concentrations of N15， then 
stimulated  with TNF-α. Dual-luciferase reporter assay system was used to 
determine the effect of N15 on human PPARs activation in Hela Cells. The 
expression of adhesion molecule in mRNA and protein levels were detected by 
Real-time PCR and Cell Enzyme linked immunosorbent assay （ ELISA ） . 
Transcriptional activation detection was used to investigate N15 activation of PPARs. 
Moncyte-binding studies were carried out using fluorescently labeled THP-1 cells and 
analysed by Fluorescened microplate reader. 















mRNA and protein levels，especially to VCAM-1. Meanwhile，N15 also inhibit the 
adherence of THP-1 to HUVEC. 
Conclusion: N15 inhibit the expression of adhesion molecules through PPARα 
pathway in human umbilical vein endothelial cell, for the prevention and treatment of 
atherosclerosis to a certain extent. 
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的，与 AS 发病相关的人 9p21 染色体单核苷酸多态性（Single Nucleotide 



































图 1.1 动脉粥样硬化形成过程 
 
1.2 PPARα及其与动脉粥样硬化的关系 
1.2.1 PPARs 的发现与分类 
1990 年，Isseman 和 Green 从小鼠肝脏克隆了一种甾体激素的受体，并根据
该受体是由过氧化物酶体增殖物所激活这一特征将其命名为过氧化物酶体增殖
物激活受体（peroxisome proliferators-activated receptors，PPARs）[12]。紧接着，
Christine Dreyer 等也从爪蟾 cDNA 文库中发现并克隆了此类受体[13]。PPARs 是
一种配体依赖的转录因子，属于核受体超家族成员，在细胞增殖、分化、代谢以
及肿瘤发生等众多生理过程中均发挥着重要作用[14-16]。已经发现的 PPARs 可分


























末端的A/B结构域（N-terminal domain, NTD ）在三种亚型中的保守性比较低，
包含一个不依赖配体的转录激活功能区AF1；此结构域中的部分氨基酸残基，可
被磷酸激酶磷酸化，如促分裂素原活化蛋白激酶(mitogen-activated protein kinases, 
MAPK) 可磷酸化该结构域中的某些丝氨酸残基，从而影响其结合的配体并调节
其转录活性 [25, 26]；中间的 C 结构域为DNA结合域( DNA Binding Domain，DBD )
则高度保守，它包含70个左右的氨基酸残基，含有两个锌指结构(zinc finger)，能
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